Free Trial
→ June 12 is 9 days away. Move now. (From Behind the Markets) (Ad)tc pixel
NASDAQ:COGT

Cogent Biosciences Q3 2025 Earnings Report

Cogent Biosciences logo
$33.24 +0.08 (+0.23%)
As of 01:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cogent Biosciences EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.54
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Cogent Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cogent Biosciences Announcement Details

Quarter
Q3 2025
Date
11/3/2025
Time
Before Market Opens
Conference Call Date
Monday, November 3, 2025
Conference Call Time
9:00AM ET

Upcoming Earnings

Cogent Biosciences' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Cogent Biosciences' Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Cogent Biosciences' Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Cogent Biosciences Earnings Headlines

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage
June 14 at 10:01 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4914866-cogent-biosciences-stock-pre-commercial-biotech-with-commercial-stage-leverage
Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow
June 13 at 1:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4914724-cogent-biosciences-inc-cogt-presents-at-european-hematology-association-eha-2026-congress
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $1.75 trillion valuation and 266 times earnings, you're buying in at the most expensive IPO in history - right when institutions who got in at $800 billion need someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure Colossus can't run without - and it's still trading at a fraction of its value.tc pixel
June 16 at 1:00 AM  |  Behind the Markets (Ad)
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association ...
June 12, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/cogent-biosciences-announces-detailed-data-from-apex-pivotal-trial-of-bezuclastinib-in-patients-with-advanced-systemic-mastocytosis-at-the-2026-european-hematology-association-eha-congress-1036245570
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
June 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/12/3311017/0/en/cogent-biosciences-announces-preclinical-data-from-novel-jak2-v617f-inhibitor-at-the-2026-european-hematology-association-eha-congress.html
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
June 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/12/3311014/0/en/cogent-biosciences-announces-detailed-data-from-apex-pivotal-trial-of-bezuclastinib-in-patients-with-advanced-systemic-mastocytosis-at-the-2026-european-hematology-association-eha-.html
See More Cogent Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email.

About Cogent Biosciences

Cogent Biosciences (NASDAQ:COGT) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors. Preclinical studies have demonstrated the candidate’s ability to deplete immunosuppressive macrophages within the tumor microenvironment, resulting in antitumor activity as a monotherapy and in combination with checkpoint inhibitors. Cogent continues to explore additional novel small molecules that can influence immune-regulatory pathways in oncology.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Cogent Biosciences completed its initial public offering in 2020 and maintains operations in key U.S. research hubs. The company leverages collaborative partnerships with academic institutions and contract research organizations to advance its pipeline efficiently. While most of its clinical programs are currently being evaluated in North America, Cogent is positioned to pursue international trial sites as it progresses through later-stage development.

Under the leadership of President and Chief Executive Officer Daniel Welch, Cogent Biosciences is guided by a management team with deep experience in oncology drug development, translational research, and regulatory strategy. The company’s board and scientific advisory committees include experts in immuno-oncology and precision medicine, supporting its mission to bring novel targeted therapies to patients with unmet medical needs.

View Cogent Biosciences Profile
Earnings Tools